Changes in 2-fluoro-2-deoxy-d-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab

Nuclear Medicine and Biology

Volumn 38, Issue 3, 2011, Pages 339-346

  Cheyne, Richard W ^a   Trembleau, Laurent ^a   McLaughlin, Abbie ^a   Smith, Tim A D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

FDG; Hexokinase; Lactate; PET; Trastuzumab

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXOKINASE; LACTIC ACID; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL LEVEL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IC 50; POSITRON EMISSION TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEXOKINASE; HUMANS; LACTIC ACID; RECEPTOR, ERBB-2; TETRAZOLIUM SALTS; THIAZOLES; TUMOR STEM CELL ASSAY;

EID: 79954425262     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.09.005     Document Type: Article

References (30)

1. Meric-Bernstam F., Hung M.C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006, 12:6326-6330.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Piccart M., Lohrisch C., Di Leo A., Larsimont D. The predictive value of HER2 in breast cancer. Oncol 2001, 61:73-82.
4. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P.A., Gilmour I.M., Robb S.D., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
5. Pietras R., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
6. Bast R.C., Ravdin P., Hayes D.F., Bates S., Fritsche H., Jessup J.M., et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
7. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
8. Ben-Haim S., Ell P. F-18-FDG PET and PET/CT in the evaluation of cancer treatment response source. J Nucl Med 2009, 50:88-99.
9. McLarty K., Fasih A., Scollard D.A., Done S.J., Vines D.C., Green D.E., et al. F-18 FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med 2009, 50:1848-1856.
10. Shah C., Miller T.W., Wyatt S.K., McKinley E.T., Olivares M.G., Sanchez V., et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009, 15:4712-4721.
11. Konecny G.E., Pegram M.D., Venkatesan N., Dering J., Ginther C., Finn R., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
12. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early glycolytic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001, 15:1406-1418.
13. Bilous M., Dowsett M., Hanna W., Isola J., Lebeau A., Moreno A., et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003, 16:173-182.
14. Pegram Y. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005, 23:391-409.
15. Rusnak D.W., Alligood K.J., Mullin R.J., Spehar G.M., Arenas-Elliott C., Martin A.M., et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib in an expanded panel of human normal and tumour cell. Cell Prolif 2007, 40:580-594.
16. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47:936-942.
17. Henriksson E., Kjellen E., Wahlberg P., Wennerberg J., Kjellstrom J.H. Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim 2006, 42:320-323.
18. Cardoso F., Durbecq V., Laes J.F., Laes J.F., Badran B., Lagneaux L., et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006, 5:2172-2181.
19. Mortimer J.E., Dehdashti F., Siegel B.A., Trinkaus K., Katzenellenbogen J.A., Welch M.J. Flare phenomenon in FDG incorporation is associated with tamoxifen treatment. J Clin Oncol 2001, 19:2797-2803.
20. Ekerljung L., Steffen A.C., Carlsson J., Lennartsson J. Effects of HER-2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006, 27:201-210.
21. Nagat Y., Lan K.H., Zhou X.Y., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
22. Aide N., Poulain L., Briand M., Dutoit S., Allouche S., Labiche A., et al. Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging 2009, 36:396-405.
23. Dorow D.S., Cullinane C., Conus N., Roselt P., Binns D., McCarthy T.J., et al. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. Eur J Nucl Med Mol Imaging 2006, 33:441-452.
24. Kawada K., Murakami K., Sato T., Kojima Y., Ebi H., Mukai H., et al. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 2007, 37:44-48.
25. Bryson J.M., Coy P.E., Gottlob K., Hay N., Robey R.B. Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem 2002, 277:11392-11400.
26. Torizuka T., Zasadny K.R., Recker B., Wahl R.L. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiol 1998, 207:767-774.
27. Lee S.C., Delikatny E.J., Poptani H., Pickup S., Glickson J.D. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP. NMR Biomed 2009, 22:259-265.
28. Witney T.H., Kettunen M.I., Day S.E., Hu D.E., Neves A.A., Gallagher F.A., et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009, 11:574-582.
29. Chakraborty A.K., Liang K., DiGiovanna M.P. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008, 68:1538-1545.
30. Daly R.J. Take your partners, please - signal diversification by the erbB family of receptor tyrosine kinases. Growth factors 1999, 16:255-263.